Replies to post #384869 on NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

The biggest bill of goods NWBO shareholders are being sold is that there is not moderate middle ground between a nearly total lack of transparency and blabbing every company secret in an online bar or over the phone to shareholders who call in to Investor Relations.

While it takes work to do both and thereby maintain a better share price and dilute shareholders when dilution has to happen at a higher share price level, that is why corporate executives are in the upper class and are paid more than we are, not to do what we could just as easily do which is say "No comment" and point to prior statements. Anybody who has watched a few congressional hearings where witnesses are getting grilled on CSPAN can do that for free.

[Poor Man -]

The big mistake we all make is we think this is a “real” company. It’s not, and there is no expectations it will ever become one. NWBO is just a vehicle to own the patents and to fund the trials, and to support Toucan’s other related ventures.

Shareholders are a necessary evil in connection with raising capital. Period. If they don’t have to engage shareholders they won’t - we all know that from years of experience.

The game is we’re betting on the success of the trial and to remain as much aligned with Toucan as reasonably possible. In other words, try and hope we’re not all screwed by NWBO/Toucan in the process.

[biosectinvestor]

This is not true. Many companies that appeared to have been completely run, trying to do exactly the same thing, have failed catastrophically. Assuming this gets to validation, which depends on the technology, and the trial and the skill managing all of it, then the fact that they thought through the production issues ahead of time, in a manner that will further make the product affordable to produce and deliver, successfully, this will have been a huge accomplishment and success beyond what most other companies could dream of achieving.

We’re along for the ride. It is not meeting everyone’s timeline for “retirement”. I get it. There are opportunity costs for choosing this ride instead of another. But those choices are the shareholder’s choices. One could trade in and out quite profitably, and choose to bet on any number of other established biotechs with revenues and products. If investors are here and holding, it can’t be that they are incompetent, it might be that the entire process of validation is incredibly long and frustrating for breakthrough biomedical products like this, but it’s not that they are incompetent fools. If it fails even, personally, I would say it was a skillfully run effort, regardless of the complaints some might have.

[biosectinvestor]

People are selling because they are often new to a company like this or this company, and usually they are traders and they want fast money, and they are not likely able to wait it out. Most traders prefer to think they can time everything. That’s kind of the basis of their entire investment premise.

Many of those trading in the markets right now are pursuing absurd meme stocks. It is basically investing with just the premise that if I am not the last tiger in and such and such a stock is promoted heavily in social media, despite having no premise for creating new value, I will get rich. Many investors right now are pursuing THAT. This is an OTC, small bio, high risk. It is what it is.

As for a company and product analogy, look again at the 2018 ASCO presentation. The “customers” were thrilled by their treatment and clearly they were handled quite nicely. The regulatory process is not a product. It has many stakeholders, not just the company, but doctors, regulatory agencies, third-party managers, and we are coming out of an unprecedented in modern times, traumatic pandemic.

[cybermich]

lol.. I think this analogy starts breaking down in your second sentence when you write.. "and you have purchased a product from a company.":) I get your frustration in a world that lacks any "customer service".. but NWBO is not selling a typical product..

"Or are you going to take your business elsewhere?"

Where else are you going to find the potential cure (or new SOC) for brain cancer?:)

[kabunushi]

We're not customers and the stock is not a product. Try again.